-
Mashup Score: 0
Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases - 10 month(s) ago
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Delayed HRQOL Outcomes Are Observed With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC - 10 month(s) ago
The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to standard of care for patients with metastatic castration-resistant prostate cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Single-Fraction SABR Yields Comparable Overall Survival to Multi-Fraction SABR for Patients With Lung Oligometastases - 10 month(s) ago
Among patients with lung oligometastases, no significant differences in overall or disease-free survival were observed with single- and multi-fraction stereotactic ablative body radiotherapy.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Opinion: The Iris App Could Be a “Game-Changer” for Patients With Cancer - 10 month(s) ago
Iris app aims to leverage accessible technology to deliver supportive care to all patients with cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dose-Dense and Dose-Intense ABVD Is Linked To Improved PFS in Frontline Treatment of Advanced Classical Hodgkin Lymphoma - 10 month(s) ago
Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or death.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Lutetium Lu 177 Vipivotide Tetraxetan Generates Enhanced Antitumor Activity in Patients With mCRPC - 10 month(s) ago
Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases - 10 month(s) ago
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Novel CAR T-Cell Therapy Shows Phase 1 Efficacy in Patients With mCRPC - 10 month(s) ago
A prostate stem cell antigen-directed CAR T-cell therapy agent showed preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Takeda has announced that they will be voluntarily withdrawing mobocertinib for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer. #oncology #nursing #NSCLC https://t.co/3PEDuFWDlp